Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After; Welcomes Gilead Sciences as Program Supporter
New initiative to be named Robert A. Winn Diversity in Clinical Trials Award Program.
he Bristol Myers Squibb Foundation (BMSF), together with its partners, National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR), announced a new name for the $100 million, five-year initiative launched in 2020 to increase diversity in clinical trials: The Robert A. Winn Diversity in Clinical Trials Award Program. Also, the program welcomed a donation of $14 million over the next four years from new program supporter, Gilead Sciences, Inc.
Read more about the new program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
